FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979501900> ?p ?o ?g. }

• W2979501900 abstract "Abstract Introduction. Resistance to therapy, rather than treatment-related mortality, is the usual cause of failure to cure AML. Typically all patients receive the same therapy despite great inter-patient variation in the mutations that underlie the disease. Thus an individualized approach to therapy might be more productive. To this end, we developed a high-throughput sensitivity assay for 160 drugs; 45 are FDA approved and 115 investigational, encompassing a wide range of targets and mechanisms of action. We previously validated the assay in 30 primary patient blast samples and 14 acute leukemia cell lines. Here we report a clinical trial (NCT01872819 at clinicaltrials.gov) utilizing this assay to select drugs for patients with refractory AML. Method. The primary objectives were to obtain assay results within 10 days and initiate treatment within 21 days. The secondary objective was to achieve a response (cytoreduction or at least partial response) greater that that expected for comparable refractory populations with other therapies. Mononuclear cells from marrow or peripheral blood were obtained by density centrifugation and enriched for blasts using magnetic bead separation if the initial sample contained < 80% blasts. Cells were incubated in coated 384 well plates overnight, then drugs were added at 8 concentrations spanning 4 log orders of magnitude, in duplicate. After 4 days, live cells were detected with CellTiter-Glo® (Promega). XLfit (idbs) was used to plot survival curves (4 parameter logistic dose fit) and to calculate EC50s. Individual drugs were chosen on the basis of EC50 and drug availability, and patients received the single agents at the accepted maximal tolerated dose. Results. Fifteen patients were enrolled. Ten had unfavorable cytogenetics, and 3 had the Flt3ITD and 1 the Flt3D835 mutation. Eight patients had antecedent hematologic disorder. They had received an average of 5 prior therapies (range 3-6). The average time from sample procurement to assay result was 5.1 days (range 4-8). Within an average of 11.6 (median 9, range 4-28) days, 13 patients received single drugs to which their cells appeared to be sensitive with an EC50 range of 0.026 - 0.175 μmol/L , including cladribine, mitoxantrone, bortezomib, or vinblastine. For the patient with the Flt3ITD mutation, the blasts exhibited sensitivity to 6 Flt3 inhibitors in the high throughput assay. Although only FDA approved drugs were able to be procured, as the pharmaceutical companies denied requests for individual patient use, most patients received a drug they had not previously received. All patients exhibited a decline in blast number after receipt of the indicated drug, on average, by 92.6% (range 80.5-99.8%). Toxicity was as expected if the patients had received standard investigational protocols for relapsed/refractory AML. Median overall survival was 88 (range 7-276) days from start of treatment. For one patient without circulating blasts, the marrow blast percent declined from 27% by flow to 0% at day 15 and also 0% at day 51. 6 of 9 evaluable participants exhibited a reduction in bone marrow blasts by flow cytometry on a day 14-21 marrow. There were also 2 patients whose day 14-21 marrows were severely hypocellular. Moreover, 1 patient achieved CR, and 2 patients, CRp, that occurred after additional cycles of combination chemotherapy regimens for 2 of the 3 patients, that included drugs identified by the high throughput assay. Conclusion. In vitro high throughput testing to guide individual treatment choice is feasible and warrants further evaluation in larger clinical trials, with panels that include investigational drugs. Disclosures Off Label Use: Cladribine is indicated for the treatment of hairy cell leukemia. Vinblastine is indicated for the treatment of Hodgkin's disease and testicular cancer, and some other cancers. Bortezomib is indicated for the treatment of multiple myeloma and mantle cell lymphoma." @default.
• W2979501900 created "2019-10-18" @default.
• W2979501900 creator A5002286772 @default.
• W2979501900 creator A5009149109 @default.
• W2979501900 creator A5015959577 @default.
• W2979501900 creator A5019322039 @default.
• W2979501900 creator A5023483498 @default.
• W2979501900 creator A5044817889 @default.
• W2979501900 creator A5047580648 @default.
• W2979501900 creator A5051018931 @default.
• W2979501900 creator A5057920623 @default.
• W2979501900 creator A5075191087 @default.
• W2979501900 date "2014-12-06" @default.
• W2979501900 modified "2023-10-02" @default.
• W2979501900 title "Feasibility Trial of Individualized Therapy for Relapsed or Refractory Acute Myeloid Leukemia Based on a High Throughput in Vitro Drug Sensitivity Assay" @default.
• W2979501900 doi "https://doi.org/10.1182/blood.v124.21.3748.3748" @default.
• W2979501900 hasPublicationYear "2014" @default.
• W2979501900 type Work @default.
• W2979501900 sameAs 2979501900 @default.
• W2979501900 citedByCount "0" @default.
• W2979501900 crossrefType "journal-article" @default.
• W2979501900 hasAuthorship W2979501900A5002286772 @default.
• W2979501900 hasAuthorship W2979501900A5009149109 @default.
• W2979501900 hasAuthorship W2979501900A5015959577 @default.
• W2979501900 hasAuthorship W2979501900A5019322039 @default.
• W2979501900 hasAuthorship W2979501900A5023483498 @default.
• W2979501900 hasAuthorship W2979501900A5044817889 @default.
• W2979501900 hasAuthorship W2979501900A5047580648 @default.
• W2979501900 hasAuthorship W2979501900A5051018931 @default.
• W2979501900 hasAuthorship W2979501900A5057920623 @default.
• W2979501900 hasAuthorship W2979501900A5075191087 @default.
• W2979501900 hasConcept C114851261 @default.
• W2979501900 hasConcept C126322002 @default.
• W2979501900 hasConcept C142424586 @default.
• W2979501900 hasConcept C143998085 @default.
• W2979501900 hasConcept C203014093 @default.
• W2979501900 hasConcept C2778729363 @default.
• W2979501900 hasConcept C535046627 @default.
• W2979501900 hasConcept C71924100 @default.
• W2979501900 hasConcept C86803240 @default.
• W2979501900 hasConcept C87355193 @default.
• W2979501900 hasConcept C89423630 @default.
• W2979501900 hasConcept C98274493 @default.
• W2979501900 hasConceptScore W2979501900C114851261 @default.
• W2979501900 hasConceptScore W2979501900C126322002 @default.
• W2979501900 hasConceptScore W2979501900C142424586 @default.
• W2979501900 hasConceptScore W2979501900C143998085 @default.
• W2979501900 hasConceptScore W2979501900C203014093 @default.
• W2979501900 hasConceptScore W2979501900C2778729363 @default.
• W2979501900 hasConceptScore W2979501900C535046627 @default.
• W2979501900 hasConceptScore W2979501900C71924100 @default.
• W2979501900 hasConceptScore W2979501900C86803240 @default.
• W2979501900 hasConceptScore W2979501900C87355193 @default.
• W2979501900 hasConceptScore W2979501900C89423630 @default.
• W2979501900 hasConceptScore W2979501900C98274493 @default.
• W2979501900 hasLocation W29795019001 @default.
• W2979501900 hasOpenAccess W2979501900 @default.
• W2979501900 hasPrimaryLocation W29795019001 @default.
• W2979501900 hasRelatedWork W1008795755 @default.
• W2979501900 hasRelatedWork W1620592016 @default.
• W2979501900 hasRelatedWork W1982432067 @default.
• W2979501900 hasRelatedWork W1988047797 @default.
• W2979501900 hasRelatedWork W2070609585 @default.
• W2979501900 hasRelatedWork W2204648307 @default.
• W2979501900 hasRelatedWork W2265325729 @default.
• W2979501900 hasRelatedWork W2340700944 @default.
• W2979501900 hasRelatedWork W2546651944 @default.
• W2979501900 hasRelatedWork W2556747587 @default.
• W2979501900 hasRelatedWork W2558541011 @default.
• W2979501900 hasRelatedWork W2560178361 @default.
• W2979501900 hasRelatedWork W2564559987 @default.
• W2979501900 hasRelatedWork W2582812279 @default.
• W2979501900 hasRelatedWork W2594352053 @default.
• W2979501900 hasRelatedWork W2594951947 @default.
• W2979501900 hasRelatedWork W2980073076 @default.
• W2979501900 hasRelatedWork W3173759495 @default.
• W2979501900 hasRelatedWork W3193664555 @default.
• W2979501900 hasRelatedWork W2189330024 @default.
• W2979501900 isParatext "false" @default.
• W2979501900 isRetracted "false" @default.
• W2979501900 magId "2979501900" @default.
• W2979501900 workType "article" @default.